STOCK TITAN

SAB BIOTHERAPEUTICS INC - SABS STOCK NEWS

Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.

Company Overview

SAB BIO (Nasdaq: SABS) is a clinical-stage biopharmaceutical company that employs a cutting-edge immunotherapy platform to develop human, multi-targeted, high-potency immunoglobulins (IgGs). As a pioneer in antibody science, the company utilizes its proprietary DiversitAb technology combined with transchromosomic (Tc) cattle to produce fully human polyclonal antibodies. This innovative approach avoids the reliance on human plasma or serum, thereby ensuring a consistent, scalable, and rapid production process that distinguishes SAB BIO from traditional biologics manufacturers.

At its core, SAB BIO is dedicated to addressing serious unmet medical needs in immune and autoimmune disorders, focusing primarily on type 1 diabetes (T1D). By harnessing advanced genetic engineering and a robust platform technology, the company aims to develop therapies that may delay the onset or progression of T1D and address other immune-related conditions. Strategic clinical programs, such as SAB-142—a human anti-thymocyte immunoglobulin—showcase the company’s commitment to generating innovative, disease-modifying solutions.

Innovative DiversitAb Platform

The DiversitAb platform is the heart of SAB BIO’s technology. It is designed to generate fully human polyclonal antibodies by leveraging transchromosomic cattle that have been genetically engineered to produce human antibodies instead of their bovine counterparts. This platform enables the rapid production of large quantities of targeted antibodies, ensuring both potency and specificity. The process not only represents a significant scientific breakthrough but also provides a reliable method to tackle a broad range of therapeutic areas without the typical constraints associated with donor-derived products.

Clinical Programs and Therapeutic Focus

SAB BIO’s lead asset, SAB-142, is a human anti-thymocyte immunoglobulin developed as a potential disease-modifying therapy for type 1 diabetes. Unlike conventional animal-derived therapies, SAB-142 is produced using the DiversitAb platform to offer a safer alternative with reduced risk of serum sickness and immunogenic reactions. The clinical development efforts, including rigorous pharmacokinetic, pharmacodynamic, and safety studies, underscore the company’s science-driven approach. This therapy is part of a broader portfolio aimed at providing multi-targeted solutions for various immune and autoimmune disorders.

Scientific Rigor and Operational Excellence

SAB BIO exemplifies expertise through its commitment to advanced antibody science and continuous innovation. The company collaborates with renowned clinical trial centers and partners in the biomedical space to conduct comprehensive trials that test not only the safety and tolerability of its products but also their potential biological activity. Each phase in clinical testing reinforces the credibility of the data and ensures adherence to the highest standards of research integrity, reinforcing the company’s position as a reliable and authoritative figure in the biopharmaceutical industry.

Market Position and Competitive Landscape

In the competitive landscape of biopharmaceutical development, SAB BIO differentiates itself through its unique DiversitAb platform and its focus on fully human biologics. The company’s approach to generating targeted polyclonal antibodies circumvents the limitations associated with traditional donor-based methods. This technological advantage positions SAB BIO as a notable innovator among peers, drawing attention from clinical experts, strategic partners, and investors who seek scientifically validated and rigorously studied immunotherapies.

Commitment to Transparency and Expertise

Each step of SAB BIO’s development is underpinned by a commitment to transparency, scientific rigor, and operational excellence. The company’s detailed clinical updates and thorough preclinical studies provide stakeholders with clear insights into its therapeutic pipeline and technological methodologies. By integrating industry-specific terminology with an accessible narrative, SAB BIO communicates its value proposition effectively, ensuring that both seasoned investors and those new to the biopharmaceutical sector can appreciate the depth and significance of its innovations.

Conclusion

Overall, SAB BIO represents a unique convergence of innovative science and strategic clinical focus. Its proprietary immunotherapy platform offers a groundbreaking method for producing fully human polyclonal antibodies, establishing a new paradigm in the treatment of type 1 diabetes and other immune-related disorders. The company’s fact-based, unbiased outlook is rooted in a commitment to excellence in research, operational transparency, and continuous scientific innovation, making it a subject of significant interest for those involved in the biopharmaceutical field.

Rhea-AI Summary

SAB BIO (SABS) announced its Q4 and full-year 2024 financial results, highlighting positive topline data from Phase 1 trials of SAB-142, their human anti-thymocyte immunoglobulin therapy for Type 1 Diabetes. The study met primary objectives for safety and pharmacodynamic activity, paving the way for Phase 2b trials expected mid-2025.

Financial highlights for FY2024 include:

  • Cash position of $20.8M (down from $56.6M in 2023)
  • R&D expenses increased to $30.3M (from $16.5M in 2023)
  • G&A expenses decreased to $14.0M (from $23.8M in 2023)
  • Net loss improved to $34.1M (from $42.2M in 2023)
  • Other net income of $8.8M (compared to $4.1M expense in 2023)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.11%
Tags
-
Rhea-AI Summary

SAB BIO (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing SAB-142, has announced its participation in two upcoming investor conferences. The company, which focuses on a novel immunotherapy platform for potentially delaying type 1 diabetes onset or progression, will be present at:

1. The Guggenheim SMID Cap Biotech Conference on February 6, 2025, featuring a fireside chat from 2:00 – 2:25pm ET

2. The Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, delivering a company presentation from 10:00 – 10:30am ET

Both events will be accessible via live webcasts and archived recordings through the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
-
Rhea-AI Summary

SAB BIO (SABS) announced positive topline data from its Phase 1 trial of SAB-142, a potential therapy for type 1 diabetes (T1D). The trial met its primary objectives for safety and pharmacodynamic activity in healthy volunteers. Key findings include:

- Favorable safety profile with doses ranging from 0.03mg/kg to 2.5mg/kg
- No reported serum sickness or anti-drug antibodies
- Demonstrated sustained immunomodulation
- Mechanism of action analogous to rabbit ATG

The company plans to advance SAB-142 into Phase 2b clinical development in 2025, targeting adult and pediatric patients with new-onset T1D. The therapy aims to be the first fully human biologic enabling outpatient dosing to delay T1D onset or progression.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-52.52%
Tags
Rhea-AI Summary

SAB BIO (NASDAQ: SABS) has announced a Research and Development webinar scheduled for January 28, 2025, at 8:00 AM EST to discuss topline data from the Phase 1 clinical trial of its lead candidate, SAB-142. The therapy is being developed as a potential disease-modifying treatment for type 1 diabetes (T1D), utilizing the company's novel immunotherapy platform that develops human anti-thymocyte immunoglobulin (hIgG).

The webinar will feature presentations from SAB BIO's management team and T1D Key Opinion Leader Dr. Michael Haller, who serves as the division chief of Pediatric Endocrinology at the University of Florida. A live Q&A session will follow the presentations, and a replay will be available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
-
Rhea-AI Summary

SAB BIO (SABS) reported Q3 2024 financial results and provided updates on its SAB-142 Type 1 diabetes program. The company completed Phase 1 enrollment with no observed serum sickness and remains on track for topline data readout by year-end. Cash position stood at $30.4 million as of September 30, 2024. Q3 net loss widened to $10.3 million ($1.12 per share) from $5.1 million ($0.97 per share) year-over-year. R&D expenses increased to $7.8 million from $4.0 million, while G&A expenses rose to $3.5 million from $2.6 million in Q3 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.22%
Tags
-
Rhea-AI Summary

SAB BIO (Nasdaq: SABS) announced that Chairman and CEO Samuel J. Reich will participate in a fireside chat at the 2024 Guggenheim Securities Healthcare Innovation Conference. The event will take place on November 11, 2024, at 3:00pm EST in Boston, MA. SAB BIO is a clinical-stage biopharmaceutical company developing a novel human anti-thymocyte immunoglobulin (hIgG) therapy aimed at delaying the onset or progression of type 1 diabetes. The fireside chat will be accessible via webcast, with a recording available through the company's website events section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
conferences
Rhea-AI Summary

SAB BIO (Nasdaq: SABS), a clinical-stage biopharmaceutical company, announced that its Chairman and CEO, Samuel J. Reich, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference. The event is scheduled for September 18th, 2024, at 8:00 am ET in New York, NY.

SAB BIO is developing a novel immunotherapy platform focusing on a human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of Type 1 Diabetes (T1D). The company has provided a webcast registration link for those interested in attending virtually. Additionally, a recording of the webcast will be available through the 'Events' section of SAB BIO's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
conferences
-
Rhea-AI Summary

SAB BIO (Nasdaq: SABS) has provided an update on its SAB-142 clinical trial at the European Association for the Study of Diabetes Annual Meeting. The company has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is now enrolling patients with type 1 diabetes in the last cohort. Notably, the target dose of 2.5mg/kg was completed with no observation of serum sickness.

SAB-142, a first-in-class human anti-thymocyte immunoglobulin, is being developed to delay the onset and progression of type 1 diabetes. The Phase 1 trial aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. The company remains on track for a topline Phase 1 data readout by the end of the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
-
Rhea-AI Summary

SAB BIO (Nasdaq: SABS), a clinical-stage biopharmaceutical company, has announced its participation in the European Association for the Study of Diabetes 60th Annual Meeting on September 9, 2024, in Madrid. The company's Executive Vice President and Chief Medical Officer, Alexandra Kropotova, MD, MBA, will present on the topic 'Protecting pancreatic beta cells with multi-target, multi-epitope immunotherapy: SAB-142'.

SAB BIO is developing a novel immunotherapy platform using human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of type 1 diabetes (T1D). The presentation will take place during the INNODIA EASD Symposium at 8:45 am in the Beijing Hall of the EASD Symposium, highlighting the company's innovative approach to T1D treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
conferences
Rhea-AI Summary

SAB BIO (Nasdaq: SABS) reported its Q2 2024 financial results and provided company updates. Key highlights include:

1. FDA clearance for SAB-142 IND application
2. Appointment of Lucy To as CFO
3. Founding of a new Clinical Advisory Board
4. Cash position of $37.3 million as of June 30, 2024
5. R&D expenses increased to $6.8 million in Q2 2024
6. Net loss of $7.3 million for Q2 2024

The company reaffirmed its cash runway into 2026 and remains focused on developing SAB-142 for delaying or stopping the progression of type 1 diabetes. SAB-142 is on track for a topline Phase 1 data readout by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.92%
Tags

FAQ

What is the current stock price of SAB BIOTHERAPEUTICS (SABS)?

The current stock price of SAB BIOTHERAPEUTICS (SABS) is $1.13 as of April 4, 2025.

What is the market cap of SAB BIOTHERAPEUTICS (SABS)?

The market cap of SAB BIOTHERAPEUTICS (SABS) is approximately 10.6M.

What is SAB BIO?

SAB BIO is a clinical-stage biopharmaceutical company that develops human immunotherapies using its innovative DiversitAb platform. It focuses on producing fully human polyclonal antibodies for the treatment of immune and autoimmune disorders.

How does the DiversitAb platform work?

The DiversitAb platform leverages genetically engineered transchromosomic cattle to produce fully human polyclonal antibodies. This method bypasses the need for human plasma and allows for rapid, scalable production of targeted antibodies.

What therapeutic areas does SAB BIO focus on?

SAB BIO focuses primarily on immune and autoimmune disorders, with a significant emphasis on type 1 diabetes. Its pipeline includes therapies aimed at modifying disease progression by targeting specific immune cells.

What is SAB-142?

SAB-142 is a human anti-thymocyte immunoglobulin developed using SAB BIO's DiversitAb platform. It is designed as a disease-modifying therapy for type 1 diabetes, aiming to delay disease onset and progression while offering an improved safety profile.

How is SAB-142 different from traditional therapies?

Unlike traditional therapies that use animal-derived antibodies, SAB-142 is fully human, reducing the risk of serum sickness and adverse immune reactions. This difference is achieved through the company’s innovative antibody production technology.

Who can benefit from SAB BIO's therapies?

Patients suffering from immune and autoimmune disorders, particularly those with type 1 diabetes, may benefit from SAB BIO's advanced immunotherapy solutions. The therapies are designed to provide targeted treatment with a strong safety profile.

What makes SAB BIO stand out in the biopharmaceutical industry?

SAB BIO stands out due to its proprietary DiversitAb platform, which enables the rapid production of fully human antibodies via genetically engineered transchromosomic cattle. This technological innovation provides a unique advantage in developing effective and safe biologic therapies.

How does SAB BIO ensure the safety and efficacy of its products?

The company conducts rigorous clinical trials and collaborates with established research centers to evaluate the safety, tolerability, and pharmacodynamic profiles of its products. Detailed clinical studies and transparent reporting help maintain high standards of scientific integrity.
SAB BIOTHERAPEUTICS INC

Nasdaq:SABS

SABS Rankings

SABS Stock Data

10.61M
7.53M
19.15%
28.69%
1.35%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
MIAMI BEACH